For patients with myeloid/lymphoid #neoplasms with FGFR1 rearrangements, #pemigatinib led to high rates of complete clinical and cytogenetic responses in chronic-phase disease, at 96% and 88%, respectively, with encouraging activity in blast-phase disease: https://ow.ly/UKCT50XKhvX
#HemeSky #OncSky

The December issue is available now! Check out the link below to read articles on #isatuximab for R/R AL #amyloidosis, ATRA-ATO combination therapy for APL, #pemigatinib for myeloid & lymphoid #neoplasms with FGFR1 rearrangements, and more: https://ow.ly/fzzm50XARLQ

Pemigatinib (Pemazyre): Uses in Cancer, Side effects, Dosage, Expectation and more - OncoDaily Learn more about Pemigatinib (Pemazyre), its uses, dosage, side effects, administration, and what to expect during treatment.

Pemigatinib (Pemazyre): Uses in Cancer, Side effects, Dosage, Expectation, and more

oncodaily.com/drugs/pemiga...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Pemigatinib #Pemazyre #FGFR

Compared to traditional chemo (ORR ~20%) or chemo + durvalumab (ORR ~27%), pemigatinib offers a precision-driven advantage for FGFR2-altered patients 🎯

#Onco404 #Cancer #Kanser #Cholangiocarcinoma #Kolanjiyokarsinom #Pemigatinib #PrecisionOncology #TargetedTherapy #ClinicalTrials #MedSky #OncSky

📍 Other FGF/FGFR alterations (cohort B), or no FGF/FGFR alterations (cohort C).

📊 Key Findings (Cohort A)
✅ Median PFS was 7.0 months.
✅ Median OS: 17.5 months (vs. ~11-13 months with the 1L chemo ± immunotherapy).

#Onco404 #Cancer #Kanser #Cholangiocarcinoma #Pemigatinib #PrecisionOncology

The phase II FIGHT-202 trial’s final results reveal pemigatinib, a selective FGFR1-3 inhibitor, shows 37% ORR in patients with advanced/metastatic #CCA harboring #FGFR2 fusions/rearrangements (cohort A) 🌟

@myesmo.bsky.social #esmoopen

#Onco404 #Cancer #Kanser #Cholangiocarcinoma #Pemigatinib

@US_FDA approves #Futibatinib for FGFR2+ Advanced #CCA. It’s been a great 2 years for BTC survivors with addition of #durvalumab + gem/cis as well as #ivosidenib (IDH1) #infigratinib #pemigatinib (FGFR2 fusion) #dabrafenib #trametinib (BRAF V600E)

@ILCAnews @MacarullaTeresa
3 @US_FDA & EMA approved #CCA targeted rx #pemigatinib #ivosidenib #dabrafenib #trametinib Unfortunately #NGS which identifies targeted rx underutilized & often not reimbursed. #NGS endorsed by @myESMO for all #CCA #ILCA22 @CCA_Alliance @curecc